Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Guardant Health: On Hold For Now
07:57pm, Thursday, 20'th Apr 2023
Shares of liquid biopsy genetic profiling test developer Guardant Health, Inc. have cratered 85% since achieving their all-time high of $181.07 in February 2021. Slowing top line growth, a very long t
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
04:05pm, Wednesday, 19'th Apr 2023
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter of 2023 after marke
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precisi
Here's Why Guardant Health (GH) Looks Ripe for Bottom Fishing
11:26am, Monday, 27'th Mar 2023
Guardant Health (GH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean
Guardant Health, Inc. (GH) Q4 2022 Earnings Call Transcript
10:35pm, Thursday, 23'rd Feb 2023
Guardant Health, Inc. (NASDAQ:GH ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Alex Kleban – Vice President-Investor Relations Helmy Eltoukhy – Chairman and
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Thursday, 23'rd Feb 2023
Guardant Health (GH) delivered earnings and revenue surprises of 2.86% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health to Participate in Upcoming March Investor Conferences
08:00am, Friday, 17'th Feb 2023
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. C
4 Undervalued Small-Cap Stocks to Buy | February 13, 2023
09:25am, Monday, 13'th Feb 2023
#Morningstar #StockMarket #Investing Plus what might rattle markets this week, and our take on interest rates. Every Monday morning, Susan Dziubinski sits down with Morningstar Chief U.S. markets stra
Guardant Health: More Catalysts To Power Leaping Growth
11:55am, Friday, 10'th Feb 2023
Despite recent data hiccups for Guardant Health, Inc., you can expect much more upsides to this stock. The flagship Guardant360 recently gained FDA approval as a companion diagnostic for the breast-ca
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
04:05pm, Wednesday, 01'st Feb 2023
PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 20
Investing in Cancer Stocks
10:43am, Monday, 30'th Jan 2023
Learn about some of the leading cancer stocks in the U.S stock market this year.
Guardant Health: Positive ECLIPSE Data Signals More Upside
08:25am, Friday, 20'th Jan 2023
Harnessing the power of a simple blood test (i.e., liquid biopsy), Guardant Health has offered hope for patients through early detection of cancer. Revenues are growing robustly while there are other
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
10:53pm, Thursday, 19'th Jan 2023
Mid-cap stocks are proving to be an attractive investment option over the past few years.
These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
10:50pm, Monday, 09'th Jan 2023
Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.
Three Pharma Stocks to Sell Before They Die
05:20pm, Saturday, 24'th Dec 2022
As we head into New Year 2023, we wanted to take a look at some of the top biotech blunders of the last several months. While many biotech stocks can hold immense profit potential, others can wipe out
